Researchers found participants with elevated Amyloid β protein (aka Aβ, a biomarker for Alzheimer’s disease) that were female, used hormone therapy (in the past or during the study), and started menopause at an earlier age were significantly more likely to have higher regional tau PET (another biomarker for Alzheimer’s disease). Of the women that used hormone therapy, the study found that starting five years or more after menopause was associated with higher tau PET than starting earlier.
